To view this email as a web page, click here.
April 11, 2017
 
ADVERTISEMENT
Ad description here
 
PHARMACISTS' REPORT
 
Trump: Tough Enough on Opioids?
The President's promises—and what critics say.
Read more
 
ADVERTISEMENT
 
What the Walgreens/Prime Therapeutics Deal Means
AllianceRx Walgreens Prime could change the specialty pharmacy landscape forever.
Read more
 
How New Biosimilars Will Drive the Market
The success of 2016's biosimilars could spell the arrival of many new ones.
Read more
 
Pharmacists Prevent Prescription Fraud
Alert pharmacists and techs are foiling crimes.
Read more
 
ADVERTISEMENT
Should you choose an independent distributor?
As an independent pharmacist, you may be subsidizing big box competitors when you work with a large distributor. What steps can you take to stop funding the competition? Read this Drug Topics Partner Perspective to learn more.
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.